In 2017, retail prices for a combined set of 754 widely used prescription drugs (brand name, generic, and specialty) increased by an average of 4.2 percent; in contrast, the general inflation rate was 2.1 percent over the same period.
The average annual increase in retail prices for the AARP combined set of drug products exceeded the corresponding rate of general inflation every year from 2006 through 2017. These findings are attributable primarily to drug price growth among brand name and specialty drugs, which more than offset often substantial price decreases among generic drugs.
In 2017, the average annual cost for the widely used prescription drugs used in our analysis was almost $20,000 per drug per year. This cost was:
• • Nearly 20 percent higher than the average Social Security retirement benefit ($16,848), • • More than three-quarters of the median income for Medicare beneficiaries ($26,200) , and • • Almost one-third of the median US household income ($60,336).
The average price of therapy for the AARP combined market basket greatly exceeded the average price of therapy for the brand name and generic market baskets. The higher price of therapy for the combined market basket is due to the markedly higher price level of specialty drug products. In 2017:
• • The average annual cost of therapy for widely used brand name drug products was $6,798, • • The average annual cost of therapy for widely used generic drug products was $365, and • • The average annual cost of therapy for widely used specialty drug products was $78,871.
Notably, the average annual cost of drug therapy for one drug used on a chronic basis would have been more than $12,500 lower in 2017 (i.e., $7,263 v.
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